Post-Inflammatory Hyperpigmentation from Acne: Insights for Optimizing Patient Outcomes

Acne and Postinflammatory Hyperpigmentation

Acne vulgaris remains one of the most common dermatologic conditions worldwide, affecting up to 85% of adolescents and a substantial proportion of adults. While inflammatory lesions are often the primary concern, postinflammatory hyperpigmentation (PIH) is increasingly recognized as a major driver of patient distress, particularly among individuals with skin of color. For many patients, PIH can be more troubling and persistent than the acne itself.

Understanding the risk factors and evidence-based treatment strategies for both acne and PIH is essential for improving long-term outcomes and patient satisfaction.

Post-inflammatory Hyperpigmentation: Why It Happens

PIH results from excess melanin production in the epidermis or abnormal melanin deposition following cytokine release associated with cutaneous inflammation. Even mild inflammatory lesions can trigger melanocyte activation, resulting in persistent pigmentary change.

Patients at highest risk:

• Fitzpatrick skin types III–VI
• Individuals with a history of pigmentary disorders
• Patients who manipulate or pick lesions
• Those with delayed or inadequate acne treatment

Epidermal PIH tends to be light brown to dark brown and may respond well to topical therapy. Dermal PIH appears blue-gray and is more resistant.

How to Manage It: Treat Acne and PIH Together

1. Early acne control
   • Preventing new inflammatory lesions is the most effective way to reduce PIH.
   • Evidence-supported options, depending on severity and other patient factors, include:
     • Benzoyl peroxide
     • Topical retinoids (adapalene, tretinoin, tazarotene)
     • Azelaic acid, which offers both anti-acne and anti-pigment benefits
     • Topical antibiotics (always combined with benzoyl peroxide)
     • Oral therapies such as doxycycline, sarecycline, spironolactone (female patients), or isotretinoin when indicated
2. Targeted PIH treatment
   • Once acne is controlled or improving, PIH-specific therapies can be layered in.
   • Evidence-supported topical agents include:
     • Hydroquinone (short-term use)
     • Azelaic acid
     • Retinoids (improve pigment through increased turnover)
     • Topical tranexamic acid
   • Procedural options include chemical peels, lasers, gentle cryotherapy, and microdermabrasion:
   • These have been used with variable results.
   • Note that peels and procedures should be performed by those with expertise in their use in patients with darker skin colors due to risk of worsening PIH.
3. Sun protection is non-negotiable
   • Daily broad-spectrum SPF 30+ is essential, as UV exposure darkens PIH and prolongs resolution. Tinted sunscreens offer the additional benefit of blocking visible light.

Counseling Patients: Setting Expectations

PIH can take months to years to resolve, depending on severity and skin type. Patients often perceive PIH as “scarring,” so education is crucial.

Key messages:

• PIH is treatable but requires consistency
• Acne control must come first
• Picking dramatically worsens pigment
• Sunscreen accelerates improvement

For many patients, especially those with darker skin colors, PIH may be as impactful as acne itself. A combined strategy that prioritizes inflammation control, incorporates targeted pigment therapies, and emphasizes photo protection can significantly improve outcomes. As clinicians, recognizing the psychosocial burden of PIH and addressing it proactively is essential for comprehensive acne care.

Resources

VisualDx